Getting your player ready...
NEW YORK — Swiss drug developer Roche boosted its hostile tender offer for biotechnology pioneer Genentech Inc. to $93 per share Friday, raising the total offer value to $45.7 billion, after its initial offer failed to pick up much support.
For weeks, Genentech’s board had been calling Roche’s $86.50 bid too low, with much of Wall Street saying shareholders likely wouldn’t bite at the offer.
